Glenmede Trust’s Cocrystal Pharma COCP Stock Holding History

Glenmede Trust’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-69	Closed	-$2	–	3072
2018 Q4	$2	Buy	+69	New	+$2.27K	﹤0.01%	2751

Other funds holding COCP

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust's COCP Position: Q1 2019 in Review

Glenmede Trust sold out of Cocrystal Pharma (COCP) in Q1 2019, closing a stake of 69 shares — an estimated $2 sold.

Glenmede Trust first reported a position in COCP in Q4 2018 and held it in 1 quarter. The position peaked at $2 in Q4 2018. 21 funds tracked by Wall St. Rank hold COCP as of Q1 2019.

Glenmede Trust reported no remaining Cocrystal Pharma position as of Q1 2019 after selling out during the quarter.
Glenmede Trust sold 69 Cocrystal Pharma shares in Q1 2019, an estimated $2.
Glenmede Trust first reported a position in Cocrystal Pharma in Q4 2018 and held it in 1 quarter.
Glenmede Trust's Cocrystal Pharma position peaked at $2 in Q4 2018.
21 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2019.

Based on Glenmede Trust's 13F filing for Q1 2019, filed 14 May 2019.